Cart
sales@molnova.com
Tivozanib
CAS No. 475108-18-0
Tivozanib( AV-951 | AV951 | AV 951 )
Catalog No. M14578 CAS No. 475108-18-0
A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 50 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 131 | In Stock |
|
| 50MG | 227 | In Stock |
|
| 100MG | 405 | In Stock |
|
| 200MG | 597 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTivozanib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.
-
DescriptionA highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3; also inhibits EphB2, PDGFR-α, PDGFR-β, c-Kit, and Tie2 (IC50=20-80 nM); inhibits VEGF-induced VEGFR-2 phosphorylation in endothelial cells (IC50=0.16 nM); p.o. active.Kidney Cancer Approved.
-
In Vitro——
-
In Vivo——
-
SynonymsAV-951 | AV951 | AV 951
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorEphB2|PDGFRα|VEGFR1|VEGFR2|VEGFR3
-
Research AreaCancer
-
IndicationKidney Cancer
Chemical Information
-
CAS Number475108-18-0
-
Formula Weight454.8631
-
Molecular FormulaC22H19ClN4O5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NC1=NOC(C)=C1)NC2=CC=C(OC3=CC=NC4=CC(OC)=C(OC)C=C34)C=C2Cl
-
Chemical NameUrea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nakamura K, et al. Cancer Res. 2006 Sep 15;66(18):9134-42.
2. Eskens FA, et al. Clin Cancer Res. 2011 Nov 15;17(22):7156-63.
3. Momeny M, et al. Sci Rep. 2017 Apr 6;7:45954.
molnova catalog
related products
-
PKI-166
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
-
Sulfatinib (b)
Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
-
DMH4
DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 μM.
